Table 2 Treatment regimens and emetogenisity

Minimal (n = 7)

Early; (−), Delayed; (−)

Tmab + VNR

2

Tmab

2

VNR

1

MTX + VCR + PSL

1

temsirolimus

1

Low (n = 38)

Early; DEX, Delayed; (−)

GEM

8

S-1 + GEM

1

nab-PTX + GEM

1

nab-PTX

3

Tmab + PTX

2

PTX

1

DTX + S-1

2

DTX + EMP

1

DTX + PSL

4

DTX

9

eribulin

1

Bmab + sLV5FU2

1

sLV5FU2

3

VTD

1

Moderate (n = 17)

Early; NK1RA + 5-HT₃RA + DEX, or 5-HT₃RA + DEX, Delayed; NK1RA + 5-HT₃RA + DEX, or 5-HT₃RA + DEX

Bmab + CBDCA + PTX

3

Pmab + FOLFOX6

2

Bmab + CapeOX

1

CapeOX

3

SOX

1

Bmab + FOLFIRI

1

Bmab + IRIS

1

IRIS

2

CPT-11

2

VCD

1

High (n = 11)

Early; NK1RA + 5-HT₃RA + DEX, Delayed; NK1RA + 5-HT₃RA + DEX

CDDP + CPT-11

4

FEC

2

EC

2

R-CHOP

3